Wellcome Trust’s Neumora Therapeutics NMRA Stock Holding History

Wellcome Trust’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.63M	Hold	3,309,123	–	–	0.06%	20
2026 Q1	$6.45M	Hold	3,309,123	–	–	0.08%	21
2025 Q4	$5.92M	Hold	3,309,123	–	–	0.06%	21
2025 Q3	$6.02M	Hold	3,309,123	–	–	0.07%	21
2025 Q2	$2.43M	Hold	3,309,123	–	–	0.03%	20
2025 Q1	$3.31M	Hold	3,309,123	–	–	0.04%	20
2024 Q4	$35.1M	Hold	3,309,123	–	–	0.42%	20
2024 Q3	$43.7M	Hold	3,309,123	–	–	0.53%	21
2024 Q2	$32.5M	Hold	3,309,123	–	–	0.42%	22
2024 Q1	$45.5M	Hold	3,309,123	–	–	0.55%	23
2023 Q4	$56.4M	Sell	3,309,123 -1	-0%	-$12	0.7%	23
2023 Q3	$46.7M	Buy	+3,309,124	New	+$41.4M	0.62%	23

Other funds holding NMRA

Addis & Hill Wayne, Pennsylvania $181M AUM 21.74% 1-Year Est. Return

Wellcome Trust's NMRA Position: Q2 2026 in Review

Wellcome Trust held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 3,309,123 shares worth $5.63M. The position accounts for 0.06% of the portfolio, ranked #20.

Wellcome Trust first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $56.4M in Q4 2023. 3 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

Wellcome Trust held 3,309,123 shares of Neumora Therapeutics worth $5.63M as of Q2 2026.
Wellcome Trust left its Neumora Therapeutics share count unchanged in Q2 2026.
Neumora Therapeutics made up 0.06% of Wellcome Trust's portfolio in Q2 2026, its #20 holding.
Wellcome Trust first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
Wellcome Trust's Neumora Therapeutics position peaked at $56.4M in Q4 2023.
3 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Wellcome Trust's 13F filing for Q2 2026, filed 9 Jul 2026.